06:37 AM EST, 01/24/2025 (MT Newswires) -- Novo Nordisk ( NVO ) said Friday its phase 1b/2a clinical trial with amycretin, a unimolecular GLP-1 and amylin receptor agonist designed for once-weekly subcutaneous administration showed positive results.

Amycretin, developed for subcutaneous and oral administration, is intended as a treatment for obesity and type 2 diabetes.

The trial, conducted in 125 adults with overweight or obesity, assessed the safety, tolerability, pharmacokinetics, and proof-of-concept over a treatment duration of up to 36 weeks. The primary endpoint of the trial was treatment-emergent adverse events.

Participants receiving amycretin achieved weight loss, with reductions of 9.7% on a 1.25 mg dose at 20 weeks, 16.2% on a 5 mg dose at 28 weeks, and 22.0% on a 20 mg dose at 36 weeks. In contrast, those on placebo experienced slight weight gains.

The safety profile was consistent with incretin-based therapies, with most adverse events being mild to moderate gastrointestinal issues.

Novo Nordisk ( NVO ) said it is currently planning further clinical development of amycretin in adults with overweight or obesity.

Novo Nordisk ( NVO ) shares were up more than 10% in recent trading.

Price: 89.88, Change: +8.78, Percent Change: +10.83